EMD-14885

Single-particle
3.7 Å
EMD-14885 Deposition: 03/05/2022
Map released: 01/06/2022
Last modified: 16/10/2024
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-14885

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-7zr7 summary report (pdf.gz) Map-7zr7 FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

OMI-42 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN

EMD-14885

Single-particle
3.7 Å
EMD-14885 Deposition: 03/05/2022
Map released: 01/06/2022
Last modified: 16/10/2024
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens, Severe acute respiratory syndrome coronavirus 2, Tequatrovirus T4
Sample: OMI-42 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN
Fitted models: 7zr7

Deposition Authors: Duyvesteyn HME, Ren J , Stuart DI
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
PUBMED: 35662412
DOI: doi:10.1016/j.cell.2022.05.014
ISSN: 1097-4172